Viatris (VTRS) FCF Payout Ratio Growth (1y) (2022 - 2026)
Viatris (VTRS) FCF Payout Ratio Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -14.68% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -49.97% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | -49.30% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.30% |
| Mar 31, 2026 | 37.82% |
| Dec 31, 2025 | -46.70% |
| Sep 30, 2025 | 11.26% |
| Jun 30, 2025 | 84.50% |
| Mar 31, 2025 | 14.99% |
| Dec 31, 2024 | 17.16% |
| Sep 30, 2024 | -1.84% |
| Jun 30, 2024 | 44.36% |
| Mar 31, 2024 | 62.35% |
| Dec 31, 2023 | -91.33% |
| Sep 30, 2023 | 2.35% |
| Jun 30, 2023 | 55.41% |
| Mar 31, 2023 | 15.27% |
| Dec 31, 2022 | 909.38% |
| Sep 30, 2022 | 37.92% |
| Jun 30, 2022 | -28.43% |